Cost Analysis of Biosimilar vs Reference Rituximab for Treating CLL and Other Diseases
Rituximab-abbs may have more economic benefits compared to rituximab in patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis, according to a study presented at the virtual 2021 ASCO Annual Meeting. These findings were presented by Elizabeth James, MD, Aventine Consulting, LLC, Marblehead, MA, lead author of the study. Rituximab-abbs, the first rituximab biosimilar approved in the US, with the expectation of reducing drug acquisition costs, is an important antibody and immune-oncology agent for the treatment of B-cell malignancies, follicular lymphoma, CLL, and NHL, while also indicated for patients with rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.